TrialThe Journal of allergy and clinical immunology2013

A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.

Lynda C Schneider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.